Specific roles for dendritic cell subsets during initiation and progression of psoriasis

Elisabeth Glitzner¹, Ana Korosec¹, Patrick M Brunner², Barbara Drobits³, Nicole Amberg¹, Helia B Schonthaler³, Tamara Kopp², Erwin F Wagner³, Georg Stingl², Martin Holcmann¹ & Maria Sibilia¹*  

Abstract

Several subtypes of APCs are found in psoriasis patients, but their involvement in disease pathogenesis is poorly understood. Here, we investigated the contribution of Langerhans cells (LCs) and plasmacytoid DCs (pDCs) in psoriasis. In human psoriatic lesions and in a psoriasis mouse model (DKO* mice), LCs are severely reduced, whereas pDCs are increased. Depletion of pDCs in DKO* mice prior to psoriasis induction resulted in a milder phenotype, whereas depletion during active disease had no effect. In contrast, while depletion of Langerin-expressing APCs before disease onset had no effect, depletion from diseased mice aggravated psoriasis symptoms. Disease aggravation was due to the absence of LCs, but not other Langerin-expressing APCs. LCs derived from DKO* mice produced increased IL-10 levels, suggesting an immunosuppressive function. Moreover, IL-23 production was high in psoriatic mice and further increased in the absence of LCs. Conversely, pDC depletion resulted in reduced IL-23 production, and therapeutic inhibition of IL-23R signaling ameliorated disease symptoms. Therefore, LCs have an anti-inflammatory role during active psoriatic disease, while pDCs exert an instigatory function during disease initiation.

Keywords AP-1; IL-23; Langerhans cells; plasmacytoid dendritic cells; psoriasis

Introduction

Psoriasis is a frequent pathology of the skin affecting about 2% of the total Western population. It is characterized by inflamed lesions that display abnormal keratinocyte proliferation and differentiation as well as prominent immune cell infiltration. Both the innate and the adaptive immune system play a role in the pathomechanism of psoriasis (Nestle et al., 2009), and several cues point to a role of keratinocytes in psoriasis etiology (Nickoloff, 2006). In human psoriatic skin, an overall increase of dendritic cells (DCs) has been found both in the epidermis and in the dermis (Lowes et al., 2005; Wagner et al., 2010). DC types that are normally absent in healthy skin, such as TNF and iNOS-producing DCs (Tip-DCs) (Lowes et al., 2005), slanDCs (Schakel et al., 2006), and plasmacytoid DCs (pDCs) (Nestle et al., 2005), have been shown to infiltrate predominantly the dermal compartment of psoriatic skin. Whereas little is known about the roles of the different DC subsets in psoriasis, recent reports indicate that DCs are an important source of IL-23, a cytokine that seems to have, along with TNF-α and IL-17, a central role in psoriasis pathology (Brummer et al., 2013; Di Cesare et al., 2009; Gunther et al., 2013; Wohm et al., 2013). Likewise, polymorphisms in the IL-23 receptor (IL-23R) have been associated with psoriasis (Di Meglio et al., 2013), and blocking IL-23 is successful in the treatment of psoriasis (Crow, 2012). Recent findings indicate that inhibitors of TNF-α signaling, which are similarly useful in therapy, seem to function via blockage of DC-derived IL-23 (Brummer et al., 2013; Gunther et al., 2013). IL-23 promotes the maintenance of T cells producing IL-17 and IL-22, which are abundant in and contribute to many of the hallmarks seen in psoriasis. In psoriatic skin, these are constituted by both CD4+ and CD8- TCRαβ+ T cells, as well as γδ T cells, and the recently discovered innate lymphoid cells (ILCs) (Dyring-Andersen et al., 2014; Lowes et al., 2014).

pDCs have been detected in low numbers even within uninvolved skin of psoriatic patients and have therefore been implicated in the conversion of healthy into lesional skin (Nestle et al., 2005). In mice engrafted with human psoriatic skin, the formation of lesions could be inhibited by pre-treatment of mice with antibodies that blocked pDC-specific type I IFN secretion (Nestle et al., 2005). Therefore, targeting pDCs as a therapeutic measure against clinically manifest psoriasis has been discussed. Another DC subset that has been suspected to be involved in psoriasis are Langerhans cells (LCs), which are constitutively resident within the epidermis. In contrast to most other immune cells that recycle from the bone marrow, the LC compartment renews under steady-state conditions from an epidermis-resident precursor population that is maintained from an early embryonic age throughout life (Chorro et al., 2009; Hoeffel et al., 2012; Merad et al., 2008). In addition, severe inflammation may provoke additional recruitment of a developmentally unrelated LC precursor from the bone marrow (Merad et al., 2008;
Nagao et al., 2012). While LCs are the only DCs present within healthy epidermis, at least four different types of DCs are present in murine dermis (Tamoutounour et al., 2013), among them a subset of DCs that expresses Langerin, termed Langerin-positive dermal DCs (Lan⁺ DCs). In humans, a counterpart for Lan⁺ DCs exists, but lacks Langerin expression, and is identified by expression of CD141 (Haniffa et al., 2012). In mice, Lan⁺ DCs can be discriminated from LCs by their additional expression of the αE integrin (CD103) (Merad et al., 2008). The role of LCs and Lan⁺ DCs could be studied using diphtheria-toxin (DT)-based mouse models that express either the DT receptor (DTR) or DT under the control of the Langerin promoter, thus allowing inducible or constitutive depletion of LCs and Lan⁺ DCs, which are herein mentioned as Lan⁺ (Lan⁺) APCs. These studies demonstrated that dependent on the context, LCs could act either pro- or anti-inflammatory (Bohr et al., 2010; Igartolo et al., 2011; Ouchi et al., 2011; Romani et al., 2012; Shkolovskaya et al., 2011), while Lan⁺ DCs have proinflammatory roles in most settings (Bedou et al., 2009; Romani et al., 2012; Senechal et al., 2014).

Psoriasis etiology is linked with an array of predisposing genes located within several psoriasis susceptibility regions (PsORS). Jun and JunB are members of the activator protein-1 (AP-1) family and act in a heterodimERIC fashion together with other AP-1 members. They are located within the susceptibility regions PsORS7 (Jun) and PsORS2 (Junb) (Schonbarten et al., 2013; Zenz et al., 2005). Interestingly, a regional loss of JunB expression is observed in human psoriatic epidermis (Guinea-Viniegra et al., 2014). A similar observation has been made for systemic lupus erythematosus (SLE) with cutaneous involvement (Pflegerl et al., 2009).

Embryonic deletion of both Jun and Junb within the epidermis leads to fatal cachexia of neonatal mice (Guinea-Viniegra et al., 2009; Zenz et al., 2005). Their deletion in adult mice via a tamoxifen (Tx)-inducible cre recombinase in keratin 5 expressing cells (Junf/f Junb fiz/ Kscreiz = DKO* mice) leads within 14 days after Tx treatment to a skin phenotype that is strongly reminiscent of human psoriasis (Zenz et al., 2005). DKO* mice present many psoriatic hallmarks, ranging from epidermal changes such as keratinocyte hyperproliferation, parakeratosis, and prominent rete ridge formation to epidermal and dermal immune infiltrates, excess of proinflammatory cytokines (Zenz et al., 2005) and hypervascularization (Schonbarten et al., 2009). Additionally, DKO* mice exhibit molecular parallels to human psoriasis, specifically a similar global protein expression pattern (Schonbarten et al., 2013), complement activation (Schonbarten et al., 2013), and increased TNF-α shedding (Zenz et al., 2005).

In this study, we employed patient biopsies, an Imiquimod (Imi)-induced skin inflammation mouse model, and the DKO* mice to investigate the function of LCs and pDCs in psoriasis. We show that LC numbers were severely diminished within human psoriatic plaques, while pDC numbers were increased. In order to investigate the consequences of LC and pDC absence during defined phases of psoriatic inflammation, we employed DKO* mice bred to either Langerin-DTR (Lan⁺DTR) mice (Kissenpffenig et al., 2005), or to BDC2-DTR mice (Swiecki et al., 2010), in which LCs or pDCs could be inducibly depleted by injection of DT, respectively. We found that depletion of pDCs prior to disease initiation attenuated disease development in the DKO* model, whereas their depletion during fully developed psoriasis-like inflammation had no effect. Conversely, LCs were not essential during the initiation of the phenotype, but their depletion during ongoing disease exacerbated skin inflammation. Our findings demonstrate that pDCs, which infiltrate during the early disease phase, are important instigators of psoriasis-like disease, while LCs serve to protect immune homeostasis in established inflammation.

**Results**

**pDCs and LCs in human psoriatic lesions**

So far, reports on LC numbers in psoriatic lesions have been inconsistent (Romani et al., 2012). Therefore, we carefully assessed LC numbers within skin biopsies from psoriatic lesions or non-lesional skin 2 cm distant from the lesion margin, as well as within skin obtained from age-matched healthy donors. While LC numbers within healthy skin and non-lesional sites of psoriatic patients were comparable, lesional skin revealed a significant reduction of LC numbers, when measured relative to epidermal area as well as to epidermal length (Fig 1A and B). Concomitantly, increased numbers of LCs were present in lesional dermis (see arrows in Fig 1A), suggesting that LC loss in psoriasis might be due to the enhanced migration of LCs through the dermis (Fig 1C).

Contrary to what was observed for LCs, the number of pDCs was significantly increased within lesional skin (Fig 1D and E), where pDCs accumulated predominantly in the papillary dermis, in line with what was previously reported for human psoriasis (Wollenberg et al., 2002). In contrast, in non-lesional skin, only very low numbers of pDCs were present (Fig 1D and E). These results show that in human psoriatic lesions, the number of LCs is dramatically decreased, whereas the number of pDCs is increased.

**Distribution of DC subtypes in inflamed skin of DKO* mice**

To mechanistically investigate the functional consequences of LC and pDC changes in psoriatic lesions, we employed the DKO* mice as a model for psoriasis. These mice develop a psoriasis-like skin disease upon tamoxifen (Tx)-induced deletion of Jun and JunB in the epidermis with K5-creiz. The psoriatic phenotype is fully developed after 14 days (d) and reproduces many major hallmarks of psoriasis (Zenz et al., 2005). On d7 after disease induction, ears and tails of DKO* mice exhibited mild erythema and scaling (Supplementary Fig S1A). Between d7 and d14, massive epidermal thickening as well as neutrophil and monocyte infiltration was observed that persisted when mice were continuously treated with Tx (Supplementary Fig S1A and B, and data not shown). No skin phenotype could be detected in Tx-treated control and Jun/JunBiz mice (Supplementary Fig S1A). The skin contains a wide spectrum of myeloid cells, which includes DCs, monocytes, and macrophages, which have been well characterized in a recent study (Tamoutounour et al., 2013). Flow cytometric analysis of this subset revealed a progressive increase in the frequency of MHC-II⁺CD11c⁺ cells in both epidermis and dermis of DKO* mice (Fig 2A, Supplementary Fig S1C). A more detailed analysis revealed that the increase in this population at d7 after disease induction is due to infiltration of several types of myeloid cells, including monocyte-derived DCs (moDCs) of the MHC-II⁺ and MHC-II⁻ subsets (Fig 2B), that have
been suggested to carry out specialized functions in inflammation (Villadangos & Schnorrer, 2007). In parallel, the frequency of MHC-II+ macrophages was increased in the dermis at d7, whereas CD11b+ DCs were not significantly altered compared to controls (Fig 2B). This demonstrates that in DKO* mice, the dermal myeloid cell composition is already considerably changed in an early phase of psoriatic inflammation. A similar pattern of myeloid cells can be found in the epidermis at d14, when cutaneous inflammation was already obvious (Fig 2B). As skin inflammation progressed, the fraction of migratory DCs also increased in auricular lymph nodes (Fig 2C, Supplementary Fig S1D). Since previous work had suggested a role for pDCs in psoriasis (Nestle et al., 2005), we analyzed their frequencies in DKO* mice. While pDCs were absent from the skin of Jun/JunBf/f mice, they were significantly increased within the epidermis and dermis of d14 DKO* mice (Fig 2D, Supplementary Fig S1E), strongly resembling human disease (Fig 1D and E) (Nestle et al., 2005). Moreover, pDCs accumulated over the disease course within auricular lymph nodes (Fig 2E). pDCs present in psoriatic skin were mostly localized within the papillary dermis (Fig 2F), but were also present within the reticular dermis and the epidermis (data not shown), as has been described for psoriatic patients (Wollenberg et al., 2002).

We next investigated LC numbers on whole-mount epidermal ear sheets and within skin cell suspensions of DKO* mice. Epidermal LC numbers had significantly increased by d7, but were markedly reduced at d14 (Fig 2G–I, Supplementary Fig S1F). This reduction was consistent with our results in psoriatic patients (Fig 1A and B). Of note, while LCs were reduced at d14, epidermal LannegCD11c+MHC-II+ APC frequency was increased at d7 and further increased until d14 (Supplementary Fig S1G). Sections of inflamed ears revealed that LCs were confined to the suprabasal epidermis and had elongated dendrites protruding toward upper epidermal layers (Supplementary Fig S1H). In the dermis and auricular lymph nodes, LCs were present with increased frequency both at d7 and d14, indicating enhanced migration of LCs in psoriatic disease, likely explaining the observed epidermal LC loss (Fig 2I and J, Supplementary Fig S1I and J). No significant increase in the frequency of activated caspase-3 positive LCs could be detected in DKO* mice at both time points (Supplementary Fig S1K), excluding apoptosis as a cause for LC loss. Additionally, several DC activation markers, including CD40, CD80, CD86, and DEC-205, were upregulated on LCs in the epidermis and in lymph nodes of DKO* mice, which is in line with enhanced migratory activity of LCs in DKO* mice (Supplementary Fig S1L).
Figure 2. APC subtypes in inflamed skin of DKO* mice.

A, B Quantification of flow cytometric analysis of (A) ear epidermal and dermal APCs (n = 7–10), and (B) ear epidermal and dermal APCs after exclusion of LCs and Lan+ DDCs. Quantification of MHC-IIlo moDCs, MHC-II+ moDCs, CD11b+ DCs, and MHC-II+ macrophages (n = 3–4).

C, D Quantification of migratory DCs (CD11c+MHC-IIhi cells) in auricular lymph nodes (n = 5–7).

D, E Quantification of (D) ear epidermal and dermal pDCs (CD45+CD11c+Bst-II+B-220 cells) (n = 5–8), and (E) pDCs (CD45+CD11c+Bst-II+B-220′CD11b′′′ cells) in auricular lymph nodes (n = 6–9) of indicated mice 7–14 days after disease induction measured by flow cytometry.

F Histological ear section stained for Bst-II (green), CD11b (red), and B-220 (blue). Nuclear staining: Hoechst (brown). Arrows indicate double positive (Bst-II/B-220) cells. Scale bar indicates 50 μm.

G Representative images of epidermal ear sheets of indicated mice stained for Langerin. Scale bars indicate 100 μm.

H Epidermal LC numbers counted on ear sheets at the indicated time points. At least three randomly chosen fields were counted for each sample (n = 9–10).

I, J Quantification of (I) ear epidermal (CD45+Lan+ cells) and dermal (CD45+Lan+CD103+ cells) LCs (n = 8–20), and (J) LCs in auricular lymph nodes (Lan+CD103+CD11b−CD103+)(n = 8–10).

K Quantification of ear dermal Lan+ DDCs (CD45+Lan+CD103+ cells) (n = 8–15) of indicated mice 7–14 days after disease induction measured by flow cytometry.

L Representative image of an immunofluorescent staining of an ear section of a day 14 DKO* mouse stained for Langerin (green) and CD103 (red). Arrows indicate double-positive cells, scale bar indicates 100 μm.

M Quantification of Lan+ DDCs (Langerin+CD8−CD11b−/−/−CD103+) in auricular lymph nodes of indicated mice (n = 8–10) by flow cytometry.

Data information: Flow cytometric quantifications are depicted as percentage of live cells. Data represent mean ± SEM. Data were analyzed using unpaired Student’s t-test (*P < 0.05, **P < 0.01, ***P < 0.001). P-values for this figure are available in Supplementary Table S3.

Source data are available online for this figure.
We also analyzed the behavior of another pro-inflammatory DC subset, Lan⁺ DDCs, during disease progression. Parallel to disease initiation, the CD103⁺ Lan⁺ DDCs infiltrated the dermis of affected skin of DKO⁺ mice (Fig 2K and L). In contrast to LCs, Lan⁺ DDC numbers were not increased within auricular lymph nodes of DKO⁺ mice (Fig 2M). Together, these results demonstrate that distinct DC subpopulations undergo spatiotemporal reorganization during psoriasis-like disease development and progression, similar to the situation in humans. LCs were increased in the epidermis during the initiation phase, whereas their frequency decreased with disease progression. This was paralleled by increased emigration of LCs to the dermis and lymph nodes. Moreover, ‘Inflammatory-type’ DCs, such as pDCs and the CD103⁺ Lan⁺ DDCs, were increased in the dermis of psoriatic mice.

**pDCs are necessary for the induction of psoriatic disease, but dispensable for its maintenance**

In order to investigate pDC function in psoriasis-like disease, we crossed DKO⁺ mice with BDCA2-DTR mice, that can be selectively depleted of pDCs by application of DT (Swiecki et al., 2010). This strategy allowed us to eliminate pDCs present in the spleen and dermis (Supplementary Fig S2A–D). To compare disease severity between individuals and time points, we estimated the disease phenotype using a blinded scoring system based on the observed redness, scaliness, and plaque size and density (see Materials and Methods for detailed description). When pDCs were depleted before disease initiation (Fig 3A), the average disease score of DKO⁺ mice was significantly reduced on d15 after disease induction, when most of the pDC-sufficient mice had developed a pronounced phenotype (Fig 3B). pDC-depleted DKO⁺ mice had visibly less inflamed skin when compared to pDC-sufficient DKO⁺ mice (Fig 3C, arrows indicating typical psoriatic lesions). Concomitantly, epidermal thickening was reduced in pDC-depleted DKO⁺ mice, while dermal thickness were not altered (Fig 3D–F). However, pDC depletion at d14 when lesions were already pronounced (Supplementary Fig S2E) had no impact on disease progression (Supplementary Fig S2F and G), or epidermal and dermal thickening (Supplementary Fig S2H, I and J). These data demonstrate that pDCs play an essential role in psoriasis initiation (Nestle et al., 2005).

Next, we reexamined our findings using another widely used mouse model of psoriasis-like disease, which is based on the topical application of the TLR7 agonist Imiquimod (Imi) (van der Fits et al., 2009). Thus, BDCA2-DTR mice were treated with either PBS or DT 1 day before Imi application (Supplementary Fig S2K). We found that depletion of pDCs prior to Imi treatment did not influence skin inflammation induced by 6 daily consecutive Imi applications (Supplementary Fig S2L and M), confirming recent findings (Wohn et al., 2013) and indicating that the two models (DKO⁺ and Imi) exhibit molecular differences.

**The psoriatic phenotype of DKO⁺ mice is exacerbated when Lan⁺ APCs are depleted during chronic psoriasis-like disease**

To investigate the function of LCs in psoriasis, we crossed DKO⁺ mice with LanDTR mice, in which DT injection ablates all Lan⁺ LCs. When pDCs were depleted in pDC-sufficient DKO⁺ mice (Fig 3C, arrows indicating typical psoriatic lesions). Concomitantly, epidermal thickening was reduced in pDC-depleted DKO⁺ mice, while dermal thickness were not altered (Fig 3D–F). However, pDC depletion at d14 when lesions were already pronounced (Supplementary Fig S2E) had no impact on disease progression (Supplementary Fig S2F and G), or epidermal and dermal thickening (Supplementary Fig S2H, I and J). These data demonstrate that pDCs play an essential role in psoriasis initiation (Nestle et al., 2005).

Next, we reexamined our findings using another widely used mouse model of psoriasis-like disease, which is based on the topical application of the TLR7 agonist Imiquimod (Imi) (van der Fits et al., 2009). Thus, BDCA2-DTR mice were treated with either PBS or DT 1 day before Imi application (Supplementary Fig S2K). We found that depletion of pDCs prior to Imi treatment did not influence skin inflammation induced by 6 daily consecutive Imi applications (Supplementary Fig S2L and M), confirming recent findings (Wohn et al., 2013) and indicating that the two models (DKO⁺ and Imi) exhibit molecular differences.

**The psoriatic phenotype of DKO⁺ mice is exacerbated when Lan⁺ APCs are depleted during chronic psoriasis-like disease**

To investigate the function of LCs in psoriasis, we crossed DKO⁺ mice with LanDTR mice, in which DT injection ablates all Lan⁺ LCs. When pDCs were depleted in pDC-sufficient DKO⁺ mice, that can be selectively depleted of pDCs by application of DT (Swiecki et al., 2010). This strategy allowed us to eliminate pDCs present in the spleen and dermis (Supplementary Fig S2A–D). To compare disease severity between individuals and time points, we estimated the disease phenotype using a blinded scoring system based on the observed redness, scaliness, and plaque size and density (see Materials and Methods for detailed description). When pDCs were depleted before disease initiation (Fig 3A), the average disease score of DKO⁺ mice was significantly reduced on d15 after disease induction, when most of the pDC-sufficient mice had developed a pronounced phenotype (Fig 3B). pDC-depleted DKO⁺ mice had visibly less inflamed skin when compared to pDC-sufficient DKO⁺ mice (Fig 3C, arrows indicating typical psoriatic lesions). Concomitantly, epidermal thickening was reduced in pDC-depleted DKO⁺ mice, while dermal thickness were not altered (Fig 3D–F). However, pDC depletion at d14 when lesions were already pronounced (Supplementary Fig S2E) had no impact on disease progression (Supplementary Fig S2F and G), or epidermal and dermal thickening (Supplementary Fig S2H, I and J). These data demonstrate that pDCs play an essential role in psoriasis initiation (Nestle et al., 2005).
APCs including epidermal LCs, and Lan⁺ DDCs which are found in the dermis (Kisselplennig et al., 2005) (Supplementary Fig S3A–D). In control Jun/JunB⁻/⁻ mice, depletion of Lan⁺ APCs did not affect skin homeostasis. To determine whether Lan⁺ APCs play a role in the induction of psoriatic disease, we depleted Lan⁺ APCs starting 1 day before disease induction (Supplementary Fig S3E). Under these conditions, mice depleted of Lan⁺ APCs displayed a similar psoriatic phenotype as their Lan⁺ APC-sufficient littermates (Supplementary Fig S3F–J). In contrast, when Lan⁺ APCs were depleted during the chronic phase of psoriasis-like skin disease on d14 (Fig 4A), we observed severe aggravation of the inflammation, whereas in Lan⁺ APC-sufficient DKO⁺ mice, the psoriatic phenotype remained relatively constant (Fig 4B). Disease aggravation was characterized by a massive increase in erythema, as well as in density and severity of psoriatic plaques (Fig 4C, Supplementary Fig S3K). Furthermore, increased epidermal hyperplasia as well as epidermal and dermal inflammation could be detected (Fig 4D). As a result, both epidermal and dermal thickening were significantly increased in Lan⁺ APC-depleted compared to Lan⁺ APC-sufficient DKO⁺ mice (Fig 4E and F).

In psoriasis, characteristic immune cell subtypes are present in the epidermis, as aggregates of neutrophils (Monro’s microabscesses), as well as inflammatory DCs (Lowes et al., 2005) and T cells (Schön & Boehncke, 2005). Flow cytometric analysis revealed that the epidermis of DKO⁺ mice contained a massive infiltrate consisting of cells of hematopoietic origin (CD45⁺) that was significantly increased in Lan⁺ APC-depleted mice (Fig 4G). The largest epidermal immune cell fraction was represented by myeloid cells consisting of a mixture of CD11b⁺ Gr-1high and CD11b⁺ Gr-1int cells, which were considerably increased in Lan⁺ APC-depleted mice (Fig 4H). Furthermore, the frequency of intraepidermal Langerin-negative (Lan⁻/⁻) infiltrating CD11c⁺ MHC-II⁺ APCs was significantly increased in Lan⁺ APC-depleted compared to Lan⁺ APC-sufficient DKO⁺ mice (Supplementary Fig S3L). In addition, epidermal T-cell frequencies were significantly higher in psoriatic DKO⁺ mice and had a tendency to be further increased upon LC depletion (Supplementary Fig S3M). The increase in T-cell frequencies in DKO⁺ mice was most likely attributed to higher numbers of TCRβ⁺ T cells, mostly of the CD4⁺ but also the CD8⁺ expressing subset, whereas the frequency of γδ T cells was similar between control and DKO⁺ mice (Supplementary Fig S3N). Since LCs had anti-inflammatory function in DKO⁺ mice, we investigated whether LC frequency and fate were altered by pDC depletion. Neither epidermal nor dermal LC numbers were significantly changed between pDC-sufficient and pDC-depleted DKO⁺ mice, excluding a counter-regulation of LC numbers through pDCs (Supplementary Fig S3O and P). Taken together, these results demonstrate that ablation of Lan⁺ APCs in the skin during the chronic phase of psoriatic disease leads to increased psoriatic inflammation, suggesting that Lan⁺ APCs have the capacity to downregulate chronic inflammation in this model.

To exclude that the aggravation of the psoriatic phenotype was due to DT-induced death of Lan⁺ APCs per se rather than their absence, we depleted Lan⁺ APCs in the Imi model of skin inflammation. Depletion of Lan⁺ APCs before Imi-induced skin inflammation (induced by 6 daily consecutive treatments) did not change its severity as measured on d7 (Supplementary Fig S4A–C). Also, depletion of Lan⁺ APCs before Imi application every other day for 14 days (Drobits et al., 2012; Palamara et al., 2004) did not impact on disease severity (Supplementary Fig S4D–F). Importantly, depletion of Lan⁺ APCs during the propagation phase at d5 of Imi treatment, when skin was visibly inflamed, did also not aggravate the observed phenotype (Supplementary Fig S4G–I), demonstrating that Lan⁺ APC depletion within inflamed skin per se does not result in an enhanced inflammatory reaction.

**LCs, but not Lan⁺ DDCs, counteract psoriatic inflammation of DKO⁺ mice**

Since injection of DT efficiently eliminated not only epidermal LCs, but also other Lan⁺ APCs, including Lan⁺ DDCs, we next addressed which of these cell types is responsible for the suppression of the psoriatic phenotype seen in DKO⁺ LanDTR mice. For this purpose, a series of bone marrow chimeric mice were generated, in which either LCs, Lan⁺ DDCs, or both could selectively be depleted. After lethal gamma irradiation followed by transplantation of a donor bone marrow, LCs remain of host origin, whereas most immune cells are replaced from the donor bone marrow (Merad et al., 2008).

We irradiated DKO⁺ or DKO⁺ LanDTR hosts and reconstituted them with bone marrow of control C57BL/6J (B6) or LanDTR (LanDTR) mice expressing CD45.1, a naturally occurring polymorphism of the CD45 antigen, as a marker. After reconstitution, psoriatic disease was induced, and DT was injected 14 days after disease induction (Fig 5A). After DT injection, DKO⁺ mice reconstituted with control B6 bone marrow (B6 → DKO⁺) had normal frequencies of LCs and Lan⁺ DDCs, and disease remained constant (Fig 5B–D and H). In DKO⁺ LanDTR mice reconstituted with a LanDTR bone marrow (LanDTR → DKO⁺ LanDTR), in which both LCs and Lan⁺ DDCs were depleted, psoriasis-like inflammation was exacerbated upon DT injection (Fig 5B, C, G, and H) similarly to what was observed with DKO⁺ LanDTR mice (Fig 4B and C). Also, DKO⁺ mice expressing LanDTR engrafted with B6 bone marrow (B6 → DKO⁺ LanDTR), in which DT application depleted LCs, but not Lan⁺ DDCs, exhibited a more severe phenotype after DT application (Fig 5B, C, E, and H). In contrast, depletion of only Lan⁺ DDCs, but not LCs in DKO⁺ mice carrying bone marrow isolated from LanDTR mice (LanDTR → DKO⁺), did not have a significant impact on disease progression (Fig 5B, C, F, and H). These results demonstrate that LCs exert an attenuating function on psoriatic skin inflammation, whereas Lan⁺ DDCs and other Langerin-expressing DC subsets were dispensable for the progression of the psoriatic phenotype.

It has been shown that application of experimental conditions involving severe skin inflammation leads to repopulation of LCs by bone marrow-derived precursors (Ginhoux et al., 2006; Nagao et al., 2012; Sere et al., 2012). In DKO⁺ mice, we noticed that LCs were in part derived from the bone marrow. To determine whether LCs repopulate the epidermis in psoriatic inflammation, and whether this leads to recruitment of a bone marrow-derived progenitor, we lethally irradiated CD45.2 expressing DKO⁺ mice and engrafted them with bone marrow isolated from C57BL/6J mice expressing CD45.1. After reconstitution, we induced psoriatic inflammation. Nine days after disease induction, we found host- as well as donor-derived LCs within the epidermis (Fig 6A and B). Interestingly, the frequency of host-derived LCs remained relatively constant in DKO⁺ mice (Fig 6C). Furthermore, while in the epidermis of control mice, only 5% of LCs were of donor origin, LCs in DKO⁺ mice
Figure 4. The psoriatic phenotype of DKO* mice is exacerbated when Lan+ APCs are depleted during chronic disease.

A Psoriatic disease was induced by five daily consecutive injections of Tx (▼), and Lan+ APCs were depleted by injection of DT (▲) at day 14 when psoriasis had developed (injections every third day). Mice were euthanized on day 21.

B Mean psoriatic phenotype score of the indicated mice was determined on day 14 and day 21 after disease induction (n = 39–41).

C Representative images of affected body parts of DKO* and DKO* LanDTR mice on day 14 and day 21 are shown. Arrows indicate sites of aggravated inflammation after Lan+ APC depletion.

D Representative H&E staining of ear sections of indicated mice on day 21. Scale bars represent 500 μm (magnification 4×) and 200 μm (magnification 10×).

E, F Histogram showing (E) epidermal and (F) dermal thickness of skin of mice of the indicated genotype. Ten randomly chosen fields of 3–4 independent images per mouse were analyzed (n = 9–19), magnification 4×.

G, H Quantification of flow cytometric analysis showing (G) ear and tail epidermal immune cells (CD45+ cells), and (H) epidermal neutrophils/monocytes (CD45+Gr-1+CD11b+ cells) of indicated mice (n = 8–12). Jun/JunBff: light gray, Jun/JunBff LanDTR: dark gray, DKO*: white, and DKO* LanDTR: black.

Data information: Flow cytometric quantifications are depicted as percentage of live cells. Data represent mean ± SEM. Data for (B), (G), and (H) were analyzed using Wilcoxon signed-rank test, and for (E) and (F), using Mann–Whitney U-test (*P < 0.05, **P < 0.01, ***P < 0.001). P-values for this figure are available in Supplementary Table S3.

Source data are available online for this figure.
were on average 40% of donor origin (Fig 6D). In line with this, donor-derived LCs exhibited a higher rate of BrdU incorporation (Fig 6E and F) and higher Ki-67 expression levels (Fig 6G, H) than host-derived LCs found in psoriasis-like disease. In contrast, topical Imi treatment did not result in substantial recruitment of bone marrow-derived LCs (Fig 6I–L). These results demonstrate that in psoriasis-like disease of DKO* mice, a considerable fraction of LCs are derived from the bone marrow. Additionally, bone marrow-born LCs exhibited higher proliferative activity and also proliferated more potently in situ within the epidermis when compared to host-derived LCs, which suggests a progressive turnover of the resident LC compartment by bone marrow-derived LCs in psoriasis-like disease.

**Figure 5. Anti-inflammatory effects are mediated by LCs, but not by Lan+ DDCs, in psoriasis.**

A DKO* LanDTR mice were irradiated and intravenously reconstituted with bone marrow isolated from either C57BL/6 (B6) or LanDTR mice expressing CD45.1. Psoriatic inflammation was induced by Tx (▼) injection. On day 14, indicated cell types were depleted by application of DT (▲). Mice were euthanized 7 days after the first DT injection.

B-C Quantification of (B) epidermal LCs (Lan+CD45* cells) (n = 4–7), and (C) dermal Lan+ DDCs (CD45*CD11c*H-2*Lan*CD103* cells) (n = 4–7) by flow cytometry.

D-G Representative pictures of affected body parts of chimeric DKO* mice: (D) DKO* mice carrying B6 bone marrow (B6 ? DKO*), (E) DKO* LanDTR mice carrying B6 bone marrow (B6 ? DKO* LanDTR), (F) DKO* mice carrying LanDTR bone marrow (LanDTR ? DKO*), and (G) DKO* LanDTR mice carrying LanDTR bone marrow (LanDTR ? DKO* LanDTR).

H Mean psoriatic phenotype score of the indicated mice was determined on day 14 and day 21 after disease induction (n = 6–8).

Data information: Flow cytometric quantifications are depicted as percentage of live cells. Data represent mean ± SEM. Data for (B) and (C) were analyzed using unpaired Student’s t-test (*P < 0.05, **P < 0.01, ***P < 0.001). P-values for this figure are available in Supplementary Table S3.

Source data are available online for this figure.

**Inhibition of the IL-23 pathway ameliorates psoriasis**

We next investigated the mechanism by which LCs ameliorate and pDCs induce psoriatic inflammation. It has previously been shown that LC-derived IL-10 can mediate tolerance in response to UVB and in a skin graft model (Yoshiki et al, 2010, 2009). Moreover, PD-L expression on mature LCs has been associated with reduced T-cell activation (Pena-Cruz et al, 2010). We therefore examined the expression of these regulatory mediators in LCs isolated from DKO* mice and found that LCs from mice with psoriasis-like skin inflammation produced substantially higher levels of IL-10 than those derived from jun/junBf/f mice (Fig 7A, Supplementary Fig S5A). Additionally, LCs isolated from the skin and skin-draining LN of
DKO* mice showed strongly increased surface expression of PD-L1 (Fig 7B). Thus, in the absence of LCs, the lack of these regulatory signals might result in increased inflammation in the skin of DKO* mice. LC depletion was not associated with changes in the numbers of regulatory T cells (Treg) in the skin or in skin-draining lymph nodes (Supplementary Fig S5B–D) excluding that reduced type-I-IFN signaling might contribute to disease amelioration (Fig 7D). Furthermore, in the absence of pDCs, the levels of IL-23 were significantly reduced in the dermis of DKO* mice (Fig 7E and F), whereas IL-17f and IL-22 levels were not significantly altered (Supplementary Fig S5H and I). Interestingly, intracellular FACS staining revealed that high levels of IL-17 were likely not produced by γδ T cells, but rather by a TCR γδαβεθ subset, most likely representing αβ T cells (Supplementary Fig S5M). Accordingly, only γδαβεθ T cells but not γδ T cells were increased in DKO* mice, and their frequency did not significantly change after pDC depletion (Supplementary Fig S5J–L). To determine whether this

In psoriasis, pDCs are the most potent producers of type I interferons (IFNs) (Nestle et al, 2005). Accordingly, in DKO* mice, epidermal expression of the interferon-responsive gene Mx1 was strongly upregulated (Fig 7D). Depletion of pDCs prior to disease induction resulted in significant reduction of Mx1 expression suggesting that reduced type-I-IFN signaling might contribute to disease amelioration (Fig 7D). Furthermore, in the absence of pDCs, the levels of IL-23 were significantly reduced in the dermis of DKO* mice (Fig 7E and F), whereas IL-17f and IL-22 levels were not significantly altered (Supplementary Fig S5H and I). Interestingly, intracellular FACS staining revealed that high levels of IL-17 were likely not produced by γδ T cells, but rather by a TCR γδαβεθ subset, most likely representing αβ T cells (Supplementary Fig S5M). Accordingly, only γδαβεθ T cells but not γδ T cells were increased in DKO* mice, and their frequency did not significantly change after pDC depletion (Supplementary Fig S5J–L). To determine whether this
differential regulation of IL-23 expression in the skin could explain the distinct effects seen in the absence of selected DC subtypes, we treated DKO* mice with a blocking monoclonal antibody directed against the IL-23R. Psoriatic mice treated with the anti-IL-23R antibody for 2 weeks, starting from d14 after disease induction showed a markedly ameliorated phenotype, while the phenotypes of mice

**Figure 7.** pDCs and LCs influence disease severity via IL-23.  
A Relative Il10 mRNA expression in isolated LCs of indicated mice (n = 7–8).  
B PD-L1 expression on epidermal and auricular lymph node LCs (n = 3).  
C Relative Il23 mRNA expression in epidermal cells of indicated mice treated as described in Fig 4A (n = 4–6).  
D Relative Mx1 mRNA expression (n = 3–7).  
E–F Relative Il23 mRNA expression in (E) epidermal (n = 3–7) and (F) dermal cells (n = 3) of indicated mice treated as described in Fig 3A.  
G Psoriatic disease was induced by five daily consecutive injections of Tx (▼); and on day 14, when psoriatic disease had developed, mice were treated with an inhibitory anti-IL-23R antibody or an isotype control every other day (▲), and euthanized on day 28.  
H Psoriatic inflammation scored at day 14 and day 28 of the indicated mice (n = 9–14).  
I Representative images of affected body parts of DKO* mice before and after treatment with anti-IL-23R or isotype control antibody.  
J Representative H&E-stained ear sections of indicated mice on day 28. Scale bars represent 100 μm.  
K, L Quantification of (K) dermal immune cells (CD45+) (n = 3–4), and (L) dermal monocytes/neutrophils (Gr-1+CD11bhi cells) within CD45+ dermal cells of indicated mice (n = 5–9) measured by flow cytometry.  

Data information: Flow cytometric quantification in (K) is depicted as percentage of live cells. Data represent mean ±SEM. Data for (A–F) and (K) were analyzed using unpaired Student’s t-test, and for (H) and (L), using Wilcoxon signed-rank test (P < 0.05, **P < 0.01) and for (H), additionally using Mann–Whitney U-test (P < 0.05). P-values for this figure are available in Supplementary Table S3. Source data are available online for this figure.
treated with isotype control antibody remained constant (Fig 7G–J). IL-23R blockade was associated with reduced psoriatic hallmarks (Fig 7J), as well as reduced amounts of intradermal immune cells (Fig 7K and L). These results demonstrate that LCs have an anti-inflammatory role during active psoriatic disease likely via the production of IL-10 and suppression of IL-23 production, while pDCs exert an instigator function during disease initiation by potentiating the IL-23 axis (Supplementary Fig S6).

**Discussion**

The contribution of the distinct DC subsets that are present in the skin of psoriatic patients is only poorly understood. Recently, two studies suggested that a dermal DC subset may be involved in psoriasis initiation via the production of IL-23 (Wohn et al, 2013), a key cytokine that mediates expansion of IL-17- and IL-22-producing cells, promoting important events in psoriasis pathology, including neutrophil infiltration and epidermal thickening (Di Cesare et al, 2009). In the present study, we report that two other skin DC subsets, pDCs and LCs, contribute selectively to distinct stages, initiation and propagation, of the inflammatory process in the skin according the model shown in Supplementary Fig S6.

pDCs were shown previously to be abundantly present within both lesional and non-lesional skin of psoriatic patients (Nestle et al, 2005). In contrast, we found significant numbers of pDCs only in psoriatic skin, with low numbers in non-lesional skin, at 2 cm distant from the adjacent lesion. Different to our investigation, the previous study analyzed skin 0.5 cm distant from the lesion, which might still represent an activated skin area in psoriasis (Nestle et al, 2005). In a mouse model of xenotransplanted human non-lesional skin of psoriatic patients, injection of anti-BDCA2 antibodies, which block pDC-specific IFN-α secretion, prevented the development of psoriatic lesions (Nestle et al, 2005). We also found that the presence of pDCs was necessary only for the initiation of psoriatic disease in DKO* mice since their depletion attenuated the psoriatic phenotype. pDCs were dispensable for maintenance of chronic inflammation, which might explain the inefficiency of anti-IFN-α-based therapies in psoriatic patients (Bissonnette et al, 2010). In a second mouse model of skin inflammation that is based on the topical application of the synthetic TLR7 agonist Imiquimod, we and others (Wohn et al, 2013) have found that the development of skin inflammation was independent of pDCs. This discrepancy to the DKO* model might be due to the fact that Imiquimod induces only an acute and transient skin inflammation, thus mimicking only very early steps in psoriasis inflammation. In contrast, the DKO* psoriasis model exhibits chronic inflammation, which remains constant over a longer period of time, thereby likely modeling the human disease.

We found that LCs were reduced in lesions of psoriatic patients as well as in the DKO* psoriatic mouse model. In DKO* mice, the disappearance of LCs was independent of the presence of pDCs, since pDC depletion in DKO* mice did not affect epidermal LC frequencies. Other groups that reported a reduction of LC numbers in psoriatic skin found that LC numbers reverted back to normal levels when patients had successfully been treated (Romani et al, 2012). In another study, following skin trauma, a portion of LCs underwent mass emigration directly after the insult, while the majority of LCs did not emigrate upon further stimulation (Dearman et al, 2004). Similarly, in patients with early-onset psoriasis, LCs from non-lesional skin were unable to migrate in response to cytokine stimulation (Cumberbatch et al, 2006). Therefore, the differential migration capacities of LCs from psoriatic skin and the fact that only about 30% of LCs can be induced to emigrate, might reflect the existence of two types of LCs in humans. In support of this hypothesis are the observations that during inflammatory conditions, LCs can originate either from bone marrow-derived precursors or from preexisting epidermal LC precursors (Chorro et al, 2009; Elnekave et al, 2014; Ginhoux et al, 2006; Nagao et al, 2012). In DKO* mice, but not in Iimi-treated mice, we found that depleted LCs were replaced from bone marrow rather than from skin-resident precursors, suggesting that two different types of LCs exist which might differently react to inflammatory conditions.

We found that elimination of LCs aggravated psoriasis-like inflammation. Lan+ DDCs, which have been shown to prime cutaneous adaptive immune responses in several instances (Romani et al, 2012), did not influence the chronic disease phase. LC depletion was associated with an increase in the frequency of epidermal immune cells known to be key mediators in psoriasis such as neutrophils, or Lanlow APCs, that are efficient producers of TNF-α in psoriasis (Lowes et al, 2005). Multiple lines of evidence argue for a local or systemic tolerogenic role of LCs during inflammatory conditions such as UV irradiation (Yoshiki et al, 2010), allergic contact dermatitis (Gomez de Aguero et al, 2012), or infections (Kautz-Neu et al, 2011). In contrast, LCs are required for the efficient generation of immune responses in other situations, such as for antigen-specific T helper 17 (TH17) cells during fungal skin infections (Igyarto et al, 2011), and vaginal immunization (Hervouet et al, 2010). In DKO* mice, LCs within the epidermis as well as in lymph nodes exhibited higher levels of CD205, PD-L1, and CD86, which have been associated with DC-mediated generation of regulatory T cells (Bonifaz et al, 2002), peripheral T-cell tolerance (Salomon et al, 2001), and protection from spontaneous autoimmunity (Probst et al, 2005). PD-L1 can be upregulated in response to IL-10, which has also been implicated in the induction of peripheral tolerance. We detected increased IL-10 expression in LCs isolated from DKO* mice. IL-10 has been shown to negatively regulate the production of proinflammatory cytokines (D’Andrea et al, 1993; de Waal Malefyt et al, 1991). IL-10 production by DCs seems to be crucial for the establishment of tolerance after UV irradiation in the skin (Ghoreschi & Dutz, 2006). Psoriatic patient skin lacks IL-10 compared to healthy individuals, which is likely due to the severe reduction of LCs in psoriatic lesions (Nickoloff et al, 1994). Therefore, LCs may directly prevent psoriasis aggravation via IL-10 and PD-L1.

An increasing body of evidence points to a critical role for IL-23 signaling in the pathogenesis of psoriasis. We found that IL-23 was increased in the skin of DKO* mice and epidermal IL-23 levels seem to be antagonistically regulated by both types of DCs investigated. In the absence of LCs during the chronic phase of psoriatic inflammation, epidermal IL-23 levels increased, while absence of pDCs during psoriasis initiation led to a reduction of dermal IL-23 levels (Supplementary Fig S6). These changes in IL-23 did not affect the levels of IL-17 and IL-22. This is surprising, given the fact that IL-23 has been reported to mediate its effects by supporting a robust IL-17 response. However, two recent papers indicate that IL-23-driven
pathology in both an asthma and a colitis model were independent of the presence of IL-17 (Izcue et al., 2008; Peng et al., 2010). Likewise, IL-23 stimulated the secretion of antimicrobial peptides in keratinocytes (Kanda & Watanabe, 2008), molecules that have been implicated in the instigation of psoriasis (Lowes et al., 2014).

Recently, in two studies, IL-23 production following stimulation with LPS and TNFα was attributed to myeloid DCs such as conventional DCs (Wohn et al., 2013), DC103+ DC, and macrophages of the dermis (Riol-Blanco et al., 2014). The latter two populations are also present in high abundance in the early stage of psoriatic inflammation of DKO* mice. However, other groups have reported that IL-23 is produced by keratinocytes in psoriasis (Piskin et al., 2006). Therefore, it is possible that DCs and macrophages are involved in the early steps of psoriasis etiology, with keratinocytes taking over the production of IL-23 once the inflammatory cascade is fully pronounced.

We found that in DKO* mice that were treated with an antibody directed against the murine IL-23R, chronic psoriasis-like inflammation was significantly ameliorated. Successful therapy of psoriatic patients with antibodies targeting molecules within the IL-23 axis, such as Ustekinumab, an antibody against the p40 subunit shared by IL-12 and IL-23, has been established in clinical trials (Rustin, 2012). Furthermore, promising results in clinical trials were also obtained with an antibody targeting the specific p19 subunit of IL-23 (Alexander, 2013). However, antibody-based therapies are costly and come with a certain risk of side effects owing to systemic immunosuppression (Crow, 2012). Thus, strategies aimed at modulating the local composition of DC subtypes in psoriatic lesions might represent a novel approach for the treatment of psoriasis in the future.

**Materials and Methods**

**Mice**

Mice harboring loxP-flanked alleles of Jun and JunB and expressing K5cre-ER<sup>T</sup> have been previously described (Zenz et al., 2005). Jun<sup>loxp</sup>JunB<sup>fl</sup>/K5cre-ER<sup>T</sup> mice (mixed background) were bred to LanDTR (Kissenpfennig et al., 2005) and BDCA2-DTR mice (Swiecki et al., 2010) (both of C57BL/6J background). To delete Jun and JunB and induce psoriasis-like disease, K5cre<sup>ER<sup>T</sup></sup> positive (DKO*) or negative (Jun/JunB<sup>f/f</sup>) mice were injected with 1 mg tamoxifen (Tx, Sigma-Aldrich) in an emulsion with sunflower seed oil (Sigma)/ethanol mixture (10:1) intraperitoneally on 5 consecutive days. Deletion of Jun and JunB was verified by PCR. Similarly, 300 ng of Diphtheria toxin (DT, List Biological Laboratories, in PBS) was injected intraperitoneally into experimental mice according to the schemes indicated in the figures. For LC depletion, DT was applied every third day, and for pDC depletion, every other day. LC and pDC depletion was > 90% as determined in the epidermis or the spleen, respectively. Mice were kept in the animal facility of the Medical University of Vienna in accordance with institutional policies and federal guidelines. Animal experiments were approved by the Animal Experimental Ethics Committee of the Medical University of Vienna and the Austrian Federal Ministry of Science and Research. (Animal license numbers: GZ 66.009/124-BrGT/2003; GZ 66.009/109-BrGT/2003; BMWF-66.009/0073-II/10b/2010 BMWF-66.009/0074-II/10b/2010; BMWFW-66.009/0200-WF/II/3b/2014; and BMWFW-66.009/0199-WF/II/3b/2014).

**Patient material, histology, and histomorphometry**

Skin was obtained under an approved protocol (EK700/2009, Ethics Committee of the Medical University of Vienna), according to the Declaration of Helsinki. Patients suffering from chronic plaque-type psoriasis with a PASI > 10 that had undergone no systemic or topical treatment for at least 4 weeks, and age-matched healthy volunteers were enrolled in the study after providing written informed consent. 6 mm punch biopsies were taken from the abdomen under local anesthesia, embedded in optimal cutting temperature compound O.C.T.™ (Tissue-Tek, Sakura Finetek, Zoeterwoude, Netherlands), and stored at −80°C until further processing. Nonlesional biopsies were taken 2 cm distant from the margin of a chronic psoriasis plaque. 7-μm cryosections were fixed in acetone and incubated with a mouse anti-Langerin or an anti-BDCA-2 antibody in PBS with 2% BSA overnight at 4°C. After incubation with 1% H<sub>2</sub>O<sub>2</sub> for 10 min, antibody binding was visualized using conventional immunohistochemical staining (Dako REAL™ Detection Systems HRP/AEC, Dako AutostainerLink 48, Dako, Glostrup, Denmark). For LC and pDC quantification, immunohistological images were acquired using a Zeiss Observer.Z1 microscope (Carl Zeiss, Oberkochen, Germany) equipped with TissueFAXS and 2 sites per sample were analyzed using HistoQuest software (both Tissue Gnostics, Vienna, Austria).

**Scoring of the psoriatic phenotype**

To monitor psoriasis severity of individual mice, a psoriasis severity scoring system modified from Singh et al (2010) was used rating the degree of erythema, swelling, and scaling of the skin separately for five dermatomes (ears, tail, paws, snout, back skin). We attributed a score of 0–4 to each of the dermatomes, defining a score of 0 as absence of pathological symptoms, 1 as isolated, sparse lesions or visible rubor, 2 as several lesions accompanied by low-grade swelling, 3 as moderate inflammation of most parts of the dermatome, and a score of 4 as intense swelling, redness and scaling of the complete dermatome and the absence of healthy skin. The phenotype score was attributed to each dermatome of each mouse in a blinded fashion and summarized as a cumulative score.

**Bone marrow chimeric mice**

Host CD45.2 mice were exposed to whole body gamma irradiation, applying the lethal dose of 10 Gray. Subsequently, CD45.1 donor bone marrow cells were isolated, and T cells were depleted either via biotinylated antibodies against CD3 (Biolegend) and CD90 (Biolegend), followed by negative magnetic sorting with IMag<sup>TM</sup> streptavidin-coated magnetic beads (BD Biosciences), or using MACS CD3 microbeads (Miltenyi) according to the manufacturer’s protocol. Of 3.5 × 10<sup>6</sup> bone marrow cells (depleted of T cells) were injected into the tail vein of each host animal, and mice were maintained for 6 weeks on acidified water. Subsequently, chimerism was verified in peripheral blood collected from the tail via flow cytometric analysis of CD45.1 and CD45.2. Chimerism was routinely > 90%.
Isolation of cells from epidermal, dermal, lymph node, and splenic suspensions

Mice were euthanized by cervical dislocation, and skin cells were isolated from ears and tails. Dorsal and ventral ear halves were separated, and tail skin was peeled from residual tissue. Skin sheets were then placed on 0.8% trypsin for 45 min (Fisher Scientific) at 37°C. Epidermis and dermis were separated, and epidermal pieces were incubated for 30 min at 37°C in PBS containing 8% FCS (PAA) and 100 µg/ml DNase I (Sigma-Aldrich). Dermal pieces were incubated in PBS with 1% FCS, 100 µg/ml DNase I, and 100 µg/ml Liberase TM (Roche) for 30 min at 37°C. Epidermal and dermal cell suspensions for flow cytometric analysis shown in Fig 2B were isolated as previously described (Tamoutounour et al., 2013). Auricular lymph nodes and spleen were isolated and incubated for 30 min at 37°C in PBS supplemented with 1% FCS, 100 µg/ml DNase I and 50 µg/ml Liberase TM. After red blood cell lysis, suspensions were filtered through a 70-µm cell strainer (BD Biosciences). Spleens were flushed with PBS containing 1% FCS, 100 µg/ml DNase I, and 50 µg/ml Liberase TM and incubated in this enzyme mix for 30 min at 37°C.

Flow cytometry

Single cell suspensions were stained with fluorescent antibodies for 30 min on ice after blocking Fc-receptors with anti-CD16/CD32 antibody. For intracellular IL-17 staining of DKO* skin, dermal and epidermal cell suspensions were pooled and stimulated for 4.5 h with 500 ng/ml PMA (Sigma) and 500 ng/ml ionomycin (Sigma) in the presence of GolgiPlug (BD Biosciences) for the last 4 h.

For a list of monoclonal antibodies used, see Supplementary Table S1. Gating for flow cytometric analysis in Fig 2B was performed as previously described (Tamoutounour et al., 2013). Auricular lymph nodes and spleen were isolated and incubated for 30 min at 37°C in PBS supplemented with 1% FCS, 100 µg/ml DNase I and 50 µg/ml Liberase TM. After red blood cell lysis, suspensions were filtered through a 70-µm cell strainer (BD Biosciences). Spleens were flushed with PBS containing 1% FCS, 100 µg/ml DNase I, and 50 µg/ml Liberase TM and incubated in this enzyme mix for 30 min at 37°C.

BrdU content was analyzed by flow cytometry using a BrdU Flow Kit (BD Biosciences).

Imiquimod treatment

Ears and/or shaved back skin of 8- to 12-week-old C57BL/6 mice were treated topically with Aldara, a 5% Imiquimod cream formulation every other day for 14 days, as previously described by our group (Drobits et al., 2012), resulting in a total of 7 imiquimod applications. Alternatively, for the data shown in Supplementary Figs S2–K and S4–D, IML was applied daily on 6 consecutive days according to the treatment regimen described by van der Fits (van der Fits et al., 2009) and mice were analyzed on day 7.

Skin thickness measurement

Ears were cut off at the base and split in half, and the lower ear half was embedded in paraffin. 4-µm sections were stained with hematoxylin and eosin (Sigma-Aldrich). Images were obtained with a Nikon eclipse 80i microscope; histomorphometric analysis was performed using the Lucia system. Epidermal and dermal thickness were measured on 10 random fields on 3–4 independent pictures per sample, magnification 4×, using Adobe Photoshop CS4 (Adobe).

Immunofluorescence stainings

Tissues were embedded in O.C.T.™ (Sakura), and 5-µm cryosections were generated and fixed in acetone before processing. Epidermal ear sheets were generated by separating epidermis from dermis with 3.8% ammonium thiocyanate (VWR) and fixed in 4% PFA (Roth). Samples were blocked for 30 min at room temperature in 1% bovine serum albumin (Sigma-Aldrich) in PBS containing 5% goat serum (PAA) and 0.1% Triton (Sigma-Aldrich) and were incubated with the indicated antibodies overnight at 4°C in the same buffer. Apoptosis of epidermal LCs was assessed by co-staining with antibodies against Langerin and active caspase-3 followed by a secondary staining with the DyLight 594 goat anti-rabbit IgG (Vector Laboratories).

Total RNA isolation and RT–PCR analysis of murine cells and tissues

Total RNA from epidermal cells was isolated with TRIzol Reagent (Invitrogen). Complementary DNA (cDNA) synthesis was performed with SuperScript First-Strand Synthesis System (Invitrogen) according to the manufacturer’s instructions. qRT–PCRs were carried out using SYBR Green Mix (Applied Biosystems), according to the manufacturer’s instructions. For a list of primer sequences employed, see Supplementary Table S2. PCRs were performed on a 7500 Fast Real-Time PCR System (Applied Biosystems, California USA) under the following conditions: an initial incubation at 50°C for 20 s and 95°C for 10 min followed by 40 cycles of 95°C for 15 s, 54°C for 1 min. Relative quantification of RNA was calculated by ΔΔCt method. Omission of cDNA or reverse transcriptase enzyme was used as negative controls.

Isolation of LCs and epidermal cells

LCs were collected as previously described (Holcmann et al, 2009).
In vivo inhibition of IL-23R signaling

The monoclonal antibody to mouse IL-23R (21A4) was generated at Merck Research Laboratories (Palo Alto). To inhibit IL-23 signaling, mice with established disease were treated by either intraperitoneal injection with 300 μg anti-IL23R antibody or an isotype mouse IgG1 antibody (27F11) every other day. Mice were grouped randomly, and phenotype score was assessed weekly. Ears were analyzed by histology, and tail skin was used for flow cytometry.

Microscopy

Confocal microscopic pictures were acquired on a Zeiss LSM700 and evaluated using the ZEN2010 software.

Graphs and statistics

Experiments were performed at least two times, and data are represented as mean ± standard error of the mean (SEM). All graphs and statistical analyses were generated GraphPad Prism4 and Adobe illustrator software. Unpaired two-tailed student’s t-test, Mann–Whitney U-test, and Wilcoxon signed-rank test were used to assess statistical significance (*P < 0.05, **P < 0.01, ***P < 0.001), as indicated in the figure legends.

Author contribution

EG designed the experiments and performed most of them. AK performed the experiments related to pDCs. PMB performed the analysis in human patient samples and together with GS participated in the interpretation of the data. BD, NA, TK, and MH performed experiments. HBS and EFW provided the DKO* mice and helped with the interpretation of data. MH participated in the design, analysis, and interpretation of data. MS conceived and supervised the whole project and provided the requested funding.

Supplementary information for this article is available online: http://embomolmed.embopress.org

Acknowledgements

We are grateful to Martina Hammer for maintaining our mouse colonies. We thank Alexandra Bogusch, Sarah Bardakji, Elena Schmidt, and Lisa Bierbaumer for excellent technical assistance. Ly5.1 mice were kindly provided by Wilfried Ellmeier. LanDTR mice and BDCA2-DTR mice were gifts of Bernard Malissen and Marco Colonna, respectively. The monoclonal anti-IL-23R antibody was a generous gift of Schering-Plough Biopharma. We thank Juan Guinea-Viegrera, Ozge Ulucan, Karin Komposch, and Rainer Zenz for critical reading of the manuscript. We express our thanks to Thomas Bauer for designing of the graphical abstract. This work was supported by the Austrian Science Fund (FWF) grants DK W1212, P18782, and SFB-23-B13 and the Austrian Federal Government’s GEN-AU program ‘Austromouse’ (GZ 200:147/1-VII/1a/2006 and 820966). B.D. was a recipient of a DocForte fellowship from the Austrian Academy of Sciences (ÖAW). E.F.W. is funded by the Banco Bilbao Vizcaya Argentaria (BBVA) Foundation and a European Research Council Advanced Grant (ERC FCK/2008/37).

Conflict of interest

The authors declare that they have no conflict of interest.

The paper explained

Problem

Psoriasis is a frequent inflammatory skin disease of unknown etiology characterized by dramatic changes in the composition of the skin’s inflammatory cells. Among these are neutrophils and T cells, and several types of dendritic cells (DCs), such as Langerhans cells (LCs) and plasmacytoid DCs (pDCs). Here, we investigated the function of these two types of DCs in the initiation and progression of psoriasis.

Results

We found a remarkable increase of pDCs in both the lesions of psoriatic patients and mouse models of psoriasis. In contrast, the resident epidermal LCs were dramatically decreased within lesional psoriatic plaques compared to healthy skin in both patients and mouse model. Using psoriatic mice, depletion of pDCs before the onset of psoriasis attenuated its severity in mouse models. However, during disease progression, psoriasis symptoms could not be ameliorated by pDC depletion. LC depletion experiments revealed that they were not involved in the initiation phase of psoriasis, but that aggravation occurred if LC were depleted during active disease.

Impact

Our results indicate that different DC subsets exert different functions during initiation and progression of psoriasis. Importantly, the resident epidermal LCs, which are gradually lost from the epidermis in the active disease phase, are responsible for keeping a suppressive skin environment via balancing the anti-inflammatory IL-10 and pro-inflammatory IL-23 axis. In future, this finding could be therapeutically explored. By supporting and strengthening the local LC network, the progression of psoriatic lesions might be prevented. This is especially important since the currently applied systemic treatments are associated with frequent side effects and are a burden for the health care system.

References

Alexander W (2013) American academy of dermatology cardiovascular research technologies 2013 american college of cardiology. P T 38: 288 – 292

Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I, Allan RS, Wojtasiak M, Shortman K, Carbone FR et al (2009) Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 10: 488 – 495

Bissonnette R, Papp K, Maari C, Yao Y, Robbie G, White WI, Le C, White B (2010) A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alpha monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol 62: 427 – 436

Bobr A, Olvera-Gomez I, Igyarto BZ, Haley KM, Hoggquist KA, Kaplan DH (2010) Acute ablation of Langerhans cells enhances skin immune responses. j Immunol 185: 4724 – 4728

Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196: 1627 – 1638

Brunner PM, Koszik F, Reininger B, Kalb ML, Bauer W, Stingl G (2013) Inflilximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages. J Allergy Clin Immunol 132(1184–1193): e1188

Chorro L, Sarde A, Li M, Woollard KJ, Champion P, Malissen B, Kisselenfennig A, Barbaroux J, Groves R, Geissmann F (2009) Langerhans cell (LC)
Langerhans cells prevent the progression of psoriasis

Elisabeth Gitzler et al

proliferation mediates neonatal development, homeostasis, and proliferation-associated expansion of the epidermal LC network. J Exp Med 206: 3089 – 3100
Crow JM (2012) Therapeutics: silencing psoriasis. Nature 492: 558 – 559
Cumberbatch M, Singh M, Dearman RJ, Young HS, Kimber I, Griffiths CE (2006) Impaired Langerhans cell migration in psoriasis. J Exp Med 203: 953 – 960
D’Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178: 1041 – 1048
Dearman RJ, Bhushan M, Cumberbatch M, Kimber I, Griffiths CE (2004) Measurement of cytokine expression and Langerhans cell migration in human skin following suction blister formation. Exp Dermatol 13: 452 – 460
De Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129: 1339 – 1350
Di Meglio P, Villanova F, Napolitano L, Tosi I, Barberio MT, Mak RK, Nutland S, Smith CH, Barker JN, Todd JA et al (2013) The IL23R A/Cln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol 133: 2381 – 2389
Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M (2012) Iliquimod clears tumors in mice independent of adaptive immunity by converting DCs into tumor-killing effector cells. J Clin Invest 122: 575 – 585
Dyng-Andersen B, Gesler C, Agerbeck C, Lauritsen JP, Gudjonsdottir SD, Skov L, Bonefeld CM (2014) Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. Br J Dermatol 170: 609 – 616
Elnekave M, Furmanov K, Shaull Y, Capucha T, Eli-Berchoer L, Zelentsova K, Holcmann M, Stoitzner P, Drobits B, Luehrs P, Stingl G, Romani N, Maurer D, Elnekave M, Furmanov K, Shaul Y, Capucha T, Eli-Berchoer L, Zelentsova K, Dyring-Andersen B, Geisler C, Agerbeck C, Lauritsen JP, Gudjonsdottir SD, Skov L, Bonefeld CM (2014) Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. J Clin Invest 122: 575 – 585
Kanda N, Watanabe S (2008) IL-12, IL-23, and IL-27 enhance human beta-defensin-2 production in keratinocytes. Eur J Immunol 38: 1287 – 1296
Kazuto-Ue K, Noordegraaf M, Dinges S, Bennett CL, John D, Clausen BE, von Stebut E (2011) Langerhans cells are negative regulators of the anti-Leishmania response. J Exp Med 208: 885 – 891
Kissenpfennig A, Henri S, Dubois B, Laplace-Builhe C, Perrin P, Romani N, Tripp CH, Douillard P, Leserman L, Kaiserlian D et al (2005) Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22: 643 – 654
Lowes MA, Chiamian F, Abello MW, Fuentes-Duculan J, Lin SL, Nussbaum R, Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T et al (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 102: 19057 – 19062
Lowes MA, Suarez-Farinillas M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32: 227 – 255
Merad M, Ginhoux F, Collin M (2008) Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Immunol 9: 935 – 947
Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T et al (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 102: 19057 – 19062
Lowes MA, Suarez-Farinillas M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32: 227 – 255
Merad M, Ginhoux F, Collin M (2008) Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Immunol 9: 935 – 947
Nagao K, Kobayashi T, Moro K, Ohyama M, Adachi T, Kitashima DY, Ueha S, Horiiuchi K, Tanizaki H, Kabashima K et al (2012) Stress-induced production of chemokines by hair follicles regulates the trafficking of dendritic cells in skin. Nat Immunol 13: 744 – 752
Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu YJ, Gilliet M (2005) Plasmacytoid dendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202: 135 – 143
Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361: 496 – 509
Nickoloff BJ, Fivenson DP, Kunkel SL, Strieter RM, Turka LA (1994) Keratinocyte interleukin-10 expression is upregulated in tape-stripped
skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Clin Immunol Immunopathol 73: 63–68

Nickoloff BJ (2006) Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 12: 102–106

Ouchi T, Kudo A, Yokouchi M, Adachi T, Kobayashi T, Kitashima DY, Fujii H, Clausen BE, Koyasu S, Amagai M et al (2011) Langerhans cell antigen capture through tight junctions confers preemptive immunity in experimental staphylococcal scaled skin syndrome. J Exp Med 208: 2607–2613

Palamara F, Meindl S, Holmman M, Luhrs P, Stingl G, Sibilia M (2004) Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 173: 3051–3061

Pena-Cruz V, McDonough SM, Diaz-Griffero F, Crum CP, Carrasco RD, Freeman GJ (2010) PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity. J Invest Dermatol 130: 2222–2230

Peng J, Yang XQ, Chang SH, Yang J, Dong C (2010) IL-23 signaling enhances Th2 polarization and regulates allergic airway inflammation. Cell Res 20: 62–71

Pfleger P, Vesely P, Hantusch B, Schlederer M, Zenz R, Janig E, Steiner G, Peng J, Yang XO, Chang SH, Yang J, Dong C (2010) 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 184: 7257–7267

Swiecki M, Gillifan S, Vermy W, Wang Y, Colonna M (2010) Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+T cell accrual. Immunity 33: 955–966

Tamoutounour S, Guilliams M, Montana Sanches F, Liu H, Terhorst D, Malosse C, Pollet E, Arduin L, Luche H, Sanchez C et al (2013) Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity 39: 925–938

Villadangos JA, Schnorrer P (2007) Intrinsically and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7: 543–555

de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries J (1993) Interleukin 10(10(–)) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209–1220

Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E (2010) Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 6: 704–714

Wohn C, Ober-Blobaum JL, Haak S, Pantelyushin S, Cheong C, Zahnner SP, Onderwater S, Kant M, Weighardt H, Holzmann B et al (2013) Langerin(+) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proc Natl Acad Sci USA 110: 10723–10728

Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, Moderer M, Rothenfusser S, Wetzel S, Endres S, Hartmann G (2002) Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 119: 1096–1102

Yoshiki R, Kabashima K, Sugita K, Atarashi K, Shimazu T, Tokura Y (2009) IL-10-producing Langerhans cells and regulatory T cells are responsible for depressed contact hypersensitivity in grafted skin. J Invest Dermatol 129: 705–713

Yoshiki R, Kabashima K, Sakabe J, Sugita K, Bito T, Nakamura M, Malissen B, Tokura Y (2010) The mandatory role of IL-10-producing and OX40 ligand-expressing mature Langerhans cells in local UVB-induced immunosuppression. J Immunol 184: 5670–5677

Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner EF (2005) Psoriasis-like skin disease and arthritis caused by inducible epidermal Jun proteins. Nature 437: 369–375

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.